Zahra Ajgal-Castel

Paris, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

HPV circulating tumor DNA to monitor response to pembrolizumab and vorinostat combination in patients with advanced HPV-related squamous-cell carcinomas.

HPV circulating tumor DNA to monitor response to pembrolizumab and vorinostat combination in patients with advanced HPV-related squamous-cell carcinomas.

Journal: ESMO open
Published: June 06, 2025

The impact of targeted therapies on molecular alterations identified by an institutional molecular tumor board: an approach based on ESCAT classification.

The impact of targeted therapies on molecular alterations identified by an institutional molecular tumor board: an approach based on ESCAT classification.

Journal: ESMO real world data and digital oncology
Published: December 03, 2024

Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial.

Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial.

Journal: Nature cancer
Published: November 13, 2024

Author Correction: The genomic and transcriptomic landscape of metastastic urothelial cancer.

Author Correction: The genomic and transcriptomic landscape of metastastic urothelial cancer.

Journal: Nature communications
Published: October 31, 2024

The genomic and transcriptomic landscape of metastastic urothelial cancer.

The genomic and transcriptomic landscape of metastastic urothelial cancer.

Journal: Nature communications
Published: March 06, 2024

Phase Ib/II trial of tipapkinogene sovacivec, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16-positive cancers.

Phase Ib/II trial of tipapkinogene sovacivec, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16-positive cancers.

Journal: European journal of cancer (Oxford, England : 1990)
Published: June 16, 2023

Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial.

Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial.

Journal: Nature communications
Published: January 06, 2023

Tumor mutational burden assessment and standardized bioinformatics approach using custom NGS panels in clinical routine.

Tumor mutational burden assessment and standardized bioinformatics approach using custom NGS panels in clinical routine.

Journal: BMC biology
Published: November 29, 2022

Association of Energy Expenditure and Efficacy in Metastatic Renal Cell Carcinoma Patients Treated with Nivolumab.

Association of Energy Expenditure and Efficacy in Metastatic Renal Cell Carcinoma Patients Treated with Nivolumab.

Journal: Cancers
Published: May 21, 2022

HDAC Inhibition to Prime Immune Checkpoint Inhibitors.

HDAC Inhibition to Prime Immune Checkpoint Inhibitors.

Journal: Cancers
Published: November 08, 2021

REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study.

REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study.

Journal: Journal of oncology
Published: September 13, 2021

Preexisting Autoantibodies and Immune Related Adverse Events in Metastatic Urothelial Carcinoma Patients Treated by Pembrolizumab.

Preexisting Autoantibodies and Immune Related Adverse Events in Metastatic Urothelial Carcinoma Patients Treated by Pembrolizumab.

Journal: Clinical genitourinary cancer
Published: June 02, 2021
Showing 1-12 of 12

Last Updated: 09/26/2026